Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1649-1654

  Flores, Raja M ^a   Riedel, Elyn ^b   Donington, Jessica Scott ^c   Alago, William ^b   Ihekweazu, Ugonna ^b   Krug, Lee ^b   Rosenzweig, Kenneth ^b   Adusumilli, Prasad S ^b   Carbone, Michele ^d   Pass, Harvey I ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d UNIVERSITY OF HAWAII   (United States)

Author keywords

Malignant pleural mesothelioma; Surveillance Epidemiology and End Results (SEER); Thoracic surgery

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HUMAN; INCIDENCE; LOBECTOMY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TERTIARY HEALTH CARE;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; AGED, 80 AND OVER; COMMUNITY-BASED PARTICIPATORY RESEARCH; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77958180661     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f1903e     Document Type: Article

References (18)

1. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006;1:289-295.
2. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.
3. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22:3451-3457. (Pubitemid 41103650)
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
5. van Meerbeeck JP, Gaafar R, Manegold C, et al; European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889. (Pubitemid 46260274)
6. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122: 788-795. (Pubitemid 33590380)
7. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997;4:628-633. (Pubitemid 127725490)
8. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-965. (Pubitemid 47511601)
9. About SEER. Background Discussion. Bethesda, MD: National Cancer Institute, Division of Cancer Control & Population Sciences, Surveillance Research Program. Available at: http://seer.cancer.gov./about/.
10. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008;135:620-626.
11. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative longterm survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-65.
12. Lee TT, Everett DL, Shu H-KG, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2002;124:1183-1189.
13. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 1993;72:389-393. (Pubitemid 23193443)
14. Treasure T, Utley M. Ten traps for the unwary in surgical series: a case study in mesothelioma reports. J Thorac Cardiovasc Surg 2007;133: 1414-1418. (Pubitemid 46805160)
15. Spiritas R, Connelly RR, Tucker MA. Survival patterns for malignant mesothelioma: the SEER experience. Int J Cancer 1988;41:525-530.
16. Vogelzang NJ, Shultz SM, Iannucci AM, et al. Malignant mesothelioma: the University of Minnesota experience. Cancer 1984;53:377-383.
17. Price B, Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology and End Results program data for 1973 through 2003. Am J Epidemiol 2004;159:107-112. (Pubitemid 38082517)
18. Bach BB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 1999;341:1198-1205. (Pubitemid 29480659)